Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin add-on to insulin in type 1 diabetes (Study Two)
2014-004599-49Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dapagliflozin in diabetes mellitus type 1 (T1D) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change in HbA1c from baseline to Week 24. Started Jun 2015; status: completed.
02
Drugs
dapagliflozin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2014-004599-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004599-49.